Navigation Links
Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models

WALTHAM, Mass., Feb. 9, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that scientists at Roswell Park Cancer Institute have demonstrated that entinostat, Syndax's novel, oral small molecule inhibitor of class I histone deacetylases, has novel immunomodulatory properties that contribute to the enhanced activity of cancer immunotherapies in models of renal and prostate cancer.  The results were published in PLoS ONE in an article titled, "Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal  and Prostate Cancer Models."

"The results demonstrate a novel immunomodulatory effect of entinostat and provide a rationale for the clinical testing of entinostat to enhance cancer immunotherapy,"  said Roberto Pili, MD, professor of oncology, chief, genitourinary section and co-leader, genitourinary program, department of medicine, Roswell Park Cancer Institute.  "We are interested in testing whether entinostat could improve the benefit seen with immunotherapies in the advanced disease population where oncology treatments are limited."

The results, published in the January 23rd issue of PLOS, show that entinostat inhibits the function of T regulatory cells that are involved in suppressing the anti-tumor activity of immune based therapies. Importantly entinostat maintained the activity of the T effector cell population.

"This exciting pre-clinical data provides new information about entinostat's mechanism of action, expanding the potential for entinostat in new combinations in solid tumors," said Joanna Horobin, MD, president and chief executive officer of Syndax.  "Because of collaborations like this one with the Roswell Park Cancer Institute, we are able to continue to investigate new combinations that could ultimately change the clinical outcomes for oncology patients who need new treatment options."

A proof-of-concept clinical study testing this hypothesis is underway with entinostat combined with interleukin-2 in renal cell cancer. Additional studies in combination with recently approved immunotherapies are planned.  Entinostat has shown effect in phase 2 clinical testing in other solid tumors including with the aromatase inhibitor exemestane in advanced breast cancer and with the epidermal growth factor receptor inhibitor erlotinib in advanced lung cancer.

About Entinostat

Syndax's lead product entinostat is a novel, oral small molecule inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression. Entinostat is differentiated from other members of the class through its unique selectivity profile, pharmacokinetic properties and safety profile. Entinostat has been studied in more than 600 cancer patients where objective tumor responses have been observed in both solid and hematologic malignancies.

Randomized, placebo-controlled phase 2 studies with entinostat have demonstrated promising results in combination with aromatase inhibitors in breast cancer (ENCORE 301) and with the EGFR-TKI erlotinib  in non-small cell lung cancer (ENCORE 401).  Results from the ENCORE clinical program have provided the basis for moving entinostat into pivotal, phase 3 testing across a platform of breast and lung cancer indications.

About Syndax

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, late-stage, oncology-focused pharmaceutical company. The company is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Syndax has worldwide rights to develop and commercialize entinostat which has shown promise in randomized clinical trials in solid tumors and in phase 2 clinical trials in Hodgkin's lymphoma. Syndax is backed by top-tier venture capital firms Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. Formed in 2005, Syndax's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2012 Wolf Prize in Medicine, the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.   For more information please visit

Syndax Contact Information
E. Blair Schoeb  
Phone: 908.277.0386                                                             

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat
2. Survival Benefit With Syndax Pharmaceuticals Entinostat Maintained in Women with Advanced Breast Cancer
3. Multiple Data Presentations on Syndax Pharmaceuticals Entinostat at Upcoming Scientific Conferences
4. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
5. Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences
6. Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
7. Syndax Pharmaceuticals Elects Arlene Morris to Board of Directors
8. Syndax Pharmaceuticals Announces Issuance of US Patent for Entinostat
9. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
10. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
11. Syndax Announces Publication of Entinostat NSCLC Data in Cancer Research
Post Your Comments:
(Date:11/24/2015)... -- Sectra (STO: SECT B) announces that ... multi-year agreement to deploy Breast Imaging PACS in ... the Breast Center a future-proof platform capable of expanding with ... announces that Breast Center of Acadiana has entered ... PACS in its two freestanding imaging centers. This investment will ...
(Date:11/24/2015)... , November 24, 2015 ... --> adds Latest Guidebook for Chinese ... 217 pages published in November 2015 to the ... business intelligence library at . ... the fastest growing global economies with a fifth ...
(Date:11/24/2015)... F1000Workspace - a research collaboration, ... was launched just six months ago. --> F1000Workspace ... for scientists - since it was launched just six months ... on to F1000Workspace - a research collaboration, reference ... launched just six months ago. --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... Many people know ... fuzzy-headedness, weight gain, cold hands, and dry skin. But many people who find their ... and exercise regimen instead of their thyroid, especially if they don’t have any of ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... offering lower prices in an early celebration of the early holiday shopping season. ... of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is in addition ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to seek treatment ... dental implants at her Mississauga, ON practice. Dr. Williams has been providing dental ... dental implants. , Missing teeth can lead to a variety of complications if ...
(Date:11/24/2015)... ... 2015 , ... In an article published November 12th by Obesity ... are or are not eligible for bariatric surgery. The article explains that candidates for ... than 100 pounds overweight, or have a BMI of 35 and over with at ...
(Date:11/24/2015)... ... November 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t ... , FDA has long asserted that design and manufacture of Laboratory ... tests and do not meet the device regulations. , Come up short in an ...
Breaking Medicine News(10 mins):